Symbols / SRTS $3.91 -1.26%
SRTS Chart
About
Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 +; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, such as applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos, as well as provide operational healthcare services for dermatology clinics. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. The company was incorporated in 2010 and is based in Boca Raton, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 64.37M |
| Enterprise Value | 50.68M | Income | -7.72M | Sales | 27.48M |
| Book/sh | 1.57 | Cash/sh | 0.87 | Dividend Yield | — |
| Payout | 0.00% | Employees | 60 | IPO | — |
| P/E | — | Forward P/E | 61.74 | PEG | — |
| P/S | 2.34 | P/B | 2.50 | P/C | — |
| EV/EBITDA | -5.11 | EV/Sales | 1.84 | Quick Ratio | 5.96 |
| Current Ratio | 9.72 | Debt/Eq | 0.86 | LT Debt/Eq | — |
| EPS (ttm) | -0.47 | EPS next Y | 0.06 | EPS Growth | 4.33% |
| Revenue Growth | 155.70% | Earnings | 2026-05-14 | ROA | -11.18% |
| ROE | -14.85% | ROIC | — | Gross Margin | 43.18% |
| Oper. Margin | 40.84% | Profit Margin | -28.09% | Shs Outstand | 16.46M |
| Shs Float | 13.68M | Short Float | 3.23% | Short Ratio | 5.09 |
| Short Interest | — | 52W High | 5.92 | 52W Low | 3.03 |
| Beta | 1.29 | Avg Volume | 99.01K | Volume | 17.72K |
| Target Price | $6.88 | Recom | Strong_buy | Prev Close | $3.96 |
| Price | $3.91 | Change | -1.26% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.88
Mean price target
2. Current target
$3.91
Latest analyst target
3. DCF / Fair value
$4.30
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.91
Low
$6.00
High
$8.00
Mean
$6.88
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-17 | main | Maxim Group | Buy → Buy | $6 |
| 2025-08-12 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-08-08 | main | Lake Street | Buy → Buy | $6 |
| 2025-05-19 | main | Maxim Group | Buy → Buy | $10 |
| 2025-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-03-11 | main | Lake Street | Buy → Buy | $13 |
| 2025-02-10 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-18 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-11-15 | main | Maxim Group | Buy → Buy | $14 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-13 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-10 | main | Maxim Group | Buy → Buy | $10 |
| 2023-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2023-08-07 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2023-05-04 | reit | HC Wainwright & Co. | — → Buy | $10 |
| 2023-05-04 | main | Alliance Global Partners | — → Buy | $7 |
| 2023-02-10 | reit | HC Wainwright & Co. | — → Buy | $16 |
| 2023-02-10 | main | Alliance Global Partners | — → Buy | $15 |
| 2022-11-04 | main | Alliance Global Partners | — → Buy | $17 |
| 2022-05-06 | main | HC Wainwright & Co. | — → Buy | $16 |
- New Sensus plan lets skin cancer clinics break even with 1 patient a month - Stock Titan Wed, 18 Feb 2026 08
- Sensus Healthcare Stock (SRTS) Opinions on Insider Buying and Strategic Updates | SRTS Stock News - Quiver Quantitative Wed, 19 Nov 2025 08
- Sensus Healthcare (NASDAQ:SRTS) stock falls 38% in past week as three-year earnings and shareholder returns continue downward trend - simplywall.st Sat, 09 Aug 2025 07
- Why The Sensus Healthcare (SRTS) Story Is Shifting As Targets Diverge On 2026 Expectations - Yahoo Finance Wed, 11 Mar 2026 16
- Sachetta Eric buys Sensus Healthcare (SRTS) shares worth $7,620 - Investing.com hu, 26 Feb 2026 08
- Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Average Rating of "Hold" by Analysts - MarketBeat Mon, 02 Mar 2026 08
- New Sensus Link software moves skin treatment workflows to the cloud - Stock Titan hu, 26 Feb 2026 08
- $SRTS stock is up 13% today. Here's what we see in our data. - Quiver Quantitative ue, 13 Jan 2026 08
- Sensus Healthcare, Inc.'s (NASDAQ:SRTS) Share Price Boosted 38% But Its Business Prospects Need A Lift Too - simplywall.st Wed, 14 Jan 2026 08
- Is It Worth Investing in Sensus Healthcare (SRTS) Based on Wall Street's Bullish Views? - Yahoo Finance Wed, 04 Jun 2025 07
- GE imaging leader joins board of non-invasive skin treatment firm - Stock Titan Wed, 07 Jan 2026 08
- Insider Purchase: CHIEF EXECUTIVE OFFICER of $SRTS Buys 25,000 Shares - Quiver Quantitative Wed, 19 Nov 2025 08
- Sensus Healthcare (NASDAQ:SRTS) shareholders have endured a 36% loss from investing in the stock three years ago - Yahoo Finance hu, 12 Feb 2026 08
- Non-invasive skin cancer treatment maker seeks spotlight at JPM Week - Stock Titan Wed, 07 Jan 2026 08
- Sensus Healthcare, Inc. (NASDAQ:SRTS) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st Sun, 15 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2000 | 7620 | — | Purchase at price 3.81 per share. | SACHETTA ERIC | Director | — | 2026-02-24 00:00:00 | D |
| 1 | 40000 | — | — | Stock Award(Grant) at price 0.00 per share. | SARDANO MICHAEL | President | — | 2025-12-12 00:00:00 | D |
| 2 | 7000 | 27510 | — | Purchase at price 3.93 per share. | SACHETTA ERIC | Director | — | 2025-11-21 00:00:00 | D |
| 3 | 25000 | 100750 | — | Purchase at price 4.03 per share. | SARDANO JOSEPH C | Chief Executive Officer | — | 2025-11-18 00:00:00 | D |
| 4 | 1000 | 3800 | — | Purchase at price 3.80 per share. | SARDANO MICHAEL | President | — | 2025-11-18 00:00:00 | D |
| 5 | 2500 | 11250 | — | Purchase at price 4.50 per share. | SACHETTA ERIC | Director | — | 2025-11-13 00:00:00 | D |
| 6 | 1000 | 4260 | — | Purchase at price 4.26 per share. | SARDANO MICHAEL | President | — | 2025-11-11 00:00:00 | D |
| 7 | 2000 | 8523 | — | Purchase at price 4.24 - 4.27 per share. | SARDANO MICHAEL | President | — | 2025-11-11 00:00:00 | D/I |
| 8 | 2000 | 8546 | — | Purchase at price 4.26 - 4.34 per share. | SARDANO MICHAEL | President | — | 2025-11-11 00:00:00 | D/I |
| 9 | 1000 | 3370 | — | Purchase at price 3.37 per share. | SARDANO MICHAEL | President | — | 2025-08-13 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 10.75K | 1.71M |
| TaxRateForCalcs | 0.20 | 0.26 | 0.26 | 0.13 |
| NormalizedEBITDA | -9.68M | 8.52M | 37.00K | 2.56M |
| TotalUnusualItems | 0.00 | 42.00K | 12.78M | -1.00K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 42.00K | 12.78M | -1.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.72M | 6.65M | 485.00K | 24.24M |
| ReconciledDepreciation | 626.00K | 432.00K | 461.00K | 509.00K |
| ReconciledCostOfRevenue | 15.62M | 17.38M | 10.35M | 14.90M |
| EBITDA | -9.68M | 8.52M | 79.00K | 15.34M |
| EBIT | -10.31M | 8.09M | -382.00K | 14.83M |
| NetInterestIncome | 683.00K | 932.00K | 992.00K | 380.00K |
| InterestExpense | 2.00K | 2.00K | ||
| InterestIncome | 683.00K | 932.00K | 992.00K | 380.00K |
| NormalizedIncome | -7.72M | 6.65M | 453.75K | 13.18M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.72M | 6.65M | 485.00K | 24.24M |
| TotalExpenses | 37.79M | 33.72M | 24.79M | 29.70M |
| TotalOperatingIncomeAsReported | -10.31M | 8.09M | -382.00K | 14.83M |
| DilutedAverageShares | 16.33M | 16.36M | 16.27M | 16.62M |
| BasicAverageShares | 16.33M | 16.31M | 16.26M | 16.48M |
| DilutedEPS | -0.47 | 0.41 | 0.03 | 1.46 |
| BasicEPS | -0.47 | 0.41 | 0.03 | 1.47 |
| DilutedNIAvailtoComStockholders | -7.72M | 6.65M | 485.00K | 24.24M |
| NetIncomeCommonStockholders | -7.72M | 6.65M | 485.00K | 24.24M |
| NetIncome | -7.72M | 6.65M | 485.00K | 24.24M |
| NetIncomeIncludingNoncontrollingInterests | -7.72M | 6.65M | 485.00K | 24.24M |
| NetIncomeContinuousOperations | -7.72M | 6.65M | 485.00K | 24.24M |
| TaxProvision | -1.91M | 2.38M | 167.00K | 3.75M |
| PretaxIncome | -9.62M | 9.02M | 652.00K | 27.99M |
| OtherIncomeExpense | 42.00K | 12.78M | -1.00K | |
| SpecialIncomeCharges | 0.00 | 42.00K | 12.78M | -1.00K |
| GainOnSaleOfPPE | 0.00 | 42.00K | 12.78M | -1.00K |
| RestructuringAndMergernAcquisition | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 683.00K | 932.00K | 992.00K | 380.00K |
| InterestExpenseNonOperating | 2.00K | 2.00K | ||
| InterestIncomeNonOperating | 683.00K | 932.00K | 992.00K | 380.00K |
| OperatingIncome | -10.31M | 8.09M | -382.00K | 14.83M |
| OperatingExpense | 22.17M | 16.34M | 14.44M | 14.80M |
| ResearchAndDevelopment | 7.78M | 4.22M | 3.68M | 3.46M |
| SellingGeneralAndAdministration | 14.40M | 12.12M | 10.76M | 11.34M |
| SellingAndMarketingExpense | 6.52M | 4.98M | 5.61M | 6.33M |
| GeneralAndAdministrativeExpense | 7.87M | 7.15M | 5.16M | 5.01M |
| OtherGandA | 7.87M | 7.15M | 5.16M | 5.01M |
| GrossProfit | 11.87M | 24.43M | 14.06M | 29.63M |
| CostOfRevenue | 15.62M | 17.38M | 10.35M | 14.90M |
| TotalRevenue | 27.48M | 41.81M | 24.41M | 44.53M |
| OperatingRevenue | 27.48M | 41.81M | 24.41M | 44.53M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 593.04K | 541.45K | 532.92K | 512.34K |
| OrdinarySharesNumber | 16.46M | 16.50M | 16.37M | 16.39M |
| ShareIssued | 17.06M | 17.04M | 16.91M | 16.90M |
| TotalDebt | 471.00K | 602.00K | 783.00K | 1.02M |
| TangibleBookValue | 48.10M | 55.83M | 48.84M | 48.07M |
| InvestedCapital | 48.10M | 55.83M | 48.84M | 48.07M |
| WorkingCapital | 41.17M | 50.85M | 45.32M | 45.54M |
| NetTangibleAssets | 48.10M | 55.83M | 48.84M | 48.07M |
| CapitalLeaseObligations | 471.00K | 602.00K | 783.00K | 1.02M |
| CommonStockEquity | 48.10M | 55.83M | 48.84M | 48.07M |
| TotalCapitalization | 48.10M | 55.83M | 48.84M | 48.07M |
| TotalEquityGrossMinorityInterest | 48.10M | 55.83M | 48.84M | 48.07M |
| StockholdersEquity | 48.10M | 55.83M | 48.84M | 48.07M |
| TreasuryStock | 3.88M | 3.57M | 3.52M | 3.43M |
| RetainedEarnings | 5.71M | 13.43M | 6.79M | 6.30M |
| AdditionalPaidInCapital | 46.09M | 45.80M | 45.41M | 45.03M |
| CapitalStock | 169.00K | 169.00K | 169.00K | 169.00K |
| CommonStock | 169.00K | 169.00K | 169.00K | 169.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 4.94M | 6.34M | 4.87M | 8.67M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 219.00K | 453.00K | 656.00K | 969.00K |
| NonCurrentDeferredLiabilities | 10.00K | 55.00K | 60.00K | 139.00K |
| NonCurrentDeferredRevenue | 10.00K | 55.00K | 60.00K | 139.00K |
| LongTermDebtAndCapitalLeaseObligation | 209.00K | 398.00K | 596.00K | 830.00K |
| LongTermCapitalLeaseObligation | 209.00K | 398.00K | 596.00K | 830.00K |
| CurrentLiabilities | 4.72M | 5.88M | 4.21M | 7.70M |
| OtherCurrentLiabilities | 403.00K | 508.00K | ||
| CurrentDeferredLiabilities | 842.00K | 541.00K | 657.00K | 693.00K |
| CurrentDeferredRevenue | 842.00K | 541.00K | 657.00K | 693.00K |
| CurrentDebtAndCapitalLeaseObligation | 262.00K | 204.00K | 187.00K | 190.00K |
| CurrentCapitalLeaseObligation | 262.00K | 204.00K | 187.00K | 190.00K |
| CurrentDebt | 51.00K | |||
| OtherCurrentBorrowings | 51.00K | |||
| CurrentProvisions | 275.00K | 329.00K | 538.00K | 403.00K |
| PayablesAndAccruedExpenses | 3.34M | 4.81M | 2.83M | 6.41M |
| Payables | 3.34M | 4.81M | 2.83M | 6.41M |
| TotalTaxPayable | 0.00 | 37.00K | 890.00K | 0.00 |
| IncomeTaxPayable | 0.00 | 37.00K | 890.00K | 0.00 |
| AccountsPayable | 3.34M | 4.81M | 2.79M | 5.52M |
| TotalAssets | 53.04M | 62.16M | 53.71M | 56.73M |
| TotalNonCurrentAssets | 7.15M | 5.43M | 4.18M | 3.49M |
| OtherNonCurrentAssets | 640.00K | 652.00K | 804.00K | 542.00K |
| NonCurrentPrepaidAssets | 24.00K | 75.00K | ||
| NonCurrentDeferredAssets | 4.08M | 2.20M | 2.14M | 1.71M |
| NonCurrentDeferredTaxesAssets | 4.08M | 2.20M | 2.14M | 1.71M |
| GoodwillAndOtherIntangibleAssets | 50.00K | 146.00K | ||
| OtherIntangibleAssets | 50.00K | 146.00K | ||
| NetPPE | 2.43M | 2.58M | 1.24M | 1.24M |
| AccumulatedDepreciation | -2.44M | -2.12M | -1.88M | -2.13M |
| GrossPPE | 4.87M | 4.70M | 3.12M | 3.37M |
| ConstructionInProgress | 474.00K | 228.00K | 0.00 | |
| OtherProperties | 4.21M | 4.30M | 2.98M | 3.21M |
| MachineryFurnitureEquipment | 186.00K | 168.00K | 145.00K | 162.00K |
| CurrentAssets | 45.89M | 56.74M | 49.53M | 53.24M |
| OtherCurrentAssets | 1.68M | 1.51M | 888.00K | 660.00K |
| PrepaidAssets | 1.52M | 3.35M | 2.99M | 6.26M |
| Inventory | 14.56M | 10.10M | 11.86M | 3.50M |
| FinishedGoods | 3.50M | 1.76M | ||
| Receivables | 6.04M | 19.73M | 10.64M | 17.30M |
| AccountsReceivable | 6.04M | 19.73M | 10.64M | 17.30M |
| AllowanceForDoubtfulAccountsReceivable | -100.00K | -100.00K | 0.00 | -107.00K |
| GrossAccountsReceivable | 6.14M | 19.83M | 10.64M | 17.41M |
| CashCashEquivalentsAndShortTermInvestments | 22.08M | 22.06M | 23.15M | 25.52M |
| CashAndCashEquivalents | 22.08M | 22.06M | 23.15M | 25.52M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 332.00K | -1.11M | -2.37M | -1.57M |
| RepurchaseOfCapitalStock | -300.00K | 0.00 | -27.00K | -3.00M |
| RepaymentOfDebt | 0.00 | -51.00K | -216.00K | |
| IssuanceOfDebt | 0.00 | |||
| CapitalExpenditure | -196.00K | -276.00K | -229.00K | -159.00K |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 2.00K |
| IncomeTaxPaidSupplementalData | 980.00K | 2.58M | 1.44M | 4.57M |
| EndCashPosition | 22.08M | 22.06M | 23.15M | 25.52M |
| BeginningCashPosition | 22.06M | 23.15M | 25.52M | 14.52M |
| ChangesInCash | 27.00K | -1.09M | -2.37M | 11.00M |
| FinancingCashFlow | -305.00K | 15.00K | -40.00K | -2.43M |
| CashFlowFromContinuingFinancingActivities | -305.00K | 15.00K | -40.00K | -2.43M |
| NetOtherFinancingCharges | -5.00K | -52.00K | -59.00K | -109.00K |
| ProceedsFromStockOptionExercised | 0.00 | 67.00K | 46.00K | 731.00K |
| NetCommonStockIssuance | -300.00K | 0.00 | -27.00K | -3.00M |
| CommonStockPayments | -300.00K | 0.00 | -27.00K | -3.00M |
| NetIssuancePaymentsOfDebt | 0.00 | -51.00K | -216.00K | |
| NetShortTermDebtIssuance | -51.00K | -216.00K | ||
| ShortTermDebtPayments | -51.00K | -216.00K | ||
| NetLongTermDebtIssuance | 0.00 | -51.00K | -216.00K | |
| LongTermDebtPayments | 0.00 | -51.00K | -216.00K | |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -196.00K | -276.00K | -187.00K | 14.84M |
| CashFlowFromContinuingInvestingActivities | -196.00K | -276.00K | -187.00K | 14.84M |
| NetOtherInvestingChanges | 42.00K | 15.00M | 257.00K | |
| NetInvestmentPurchaseAndSale | 0.00 | |||
| SaleOfInvestment | 0.00 | |||
| NetPPEPurchaseAndSale | -196.00K | -276.00K | -229.00K | -159.00K |
| SaleOfPPE | 257.00K | |||
| PurchaseOfPPE | -196.00K | -276.00K | -229.00K | -159.00K |
| OperatingCashFlow | 528.00K | -831.00K | -2.15M | -1.41M |
| CashFlowFromContinuingOperatingActivities | 528.00K | -831.00K | -2.15M | -1.41M |
| ChangeInWorkingCapital | 8.66M | -8.55M | -3.56M | -12.92M |
| ChangeInOtherWorkingCapital | -301.00K | -585.00K | -583.00K | -1.43M |
| ChangeInOtherCurrentLiabilities | -242.00K | -181.00K | -201.00K | -199.00K |
| ChangeInOtherCurrentAssets | -164.00K | -467.00K | -540.00K | 294.00K |
| ChangeInPayablesAndAccruedExpense | -1.47M | 1.98M | -3.58M | 1.69M |
| ChangeInPayable | -1.47M | 1.98M | -3.58M | 1.69M |
| ChangeInAccountPayable | -1.47M | 2.02M | -2.73M | 799.00K |
| ChangeInTaxPayable | 0.00 | -37.00K | -853.00K | 890.00K |
| ChangeInIncomeTaxPayable | 0.00 | -37.00K | -853.00K | 890.00K |
| ChangeInPrepaidAssets | 1.82M | -361.00K | 3.27M | -4.77M |
| ChangeInInventory | -4.63M | 268.00K | -8.58M | -3.19M |
| ChangeInReceivables | 13.65M | -9.21M | 6.65M | -5.31M |
| ChangesInAccountReceivables | 13.65M | -9.21M | 6.65M | -5.31M |
| OtherNonCashItems | -38.00K | |||
| StockBasedCompensation | 295.00K | 323.00K | 328.00K | 187.00K |
| ProvisionandWriteOffofAssets | 547.00K | 378.00K | 603.00K | 722.00K |
| AssetImpairmentCharge | 123.00K | 7.00K | 145.00K | 166.00K |
| DeferredTax | -1.88M | -57.00K | -427.00K | -1.71M |
| DeferredIncomeTax | -1.88M | -57.00K | -427.00K | -1.71M |
| DepreciationAmortizationDepletion | 626.00K | 432.00K | 461.00K | 509.00K |
| DepreciationAndAmortization | 626.00K | 432.00K | 461.00K | 509.00K |
| AmortizationCashFlow | 96.00K | 104.00K | ||
| AmortizationOfIntangibles | 96.00K | 104.00K | ||
| Depreciation | 626.00K | 432.00K | 461.00K | 509.00K |
| OperatingGainsLosses | -42.00K | -12.58M | 47.00K | |
| GainLossOnSaleOfPPE | 0.00 | 47.00K | ||
| NetIncomeFromContinuingOperations | -7.72M | 6.65M | 485.00K | 24.24M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SRTS
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|